Unexpected Race-Based Findings in Novel Prostate Cancer Study
email article Black men with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (Zytiga) plus prednisone had similar survival outcomes but more toxicity compared with white men, a multicenter prospective study showed. Median radiographic progression-free survival (PFS), the study's primary outcome, was similar between the two groups, at 16.6 and 16.8 months for the Black and white patients, respectively, reported Daniel George, MD, of Duke University Medical Center in Durham, North Carolina, and colleagues. And median overall survival was nearly ide...